The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma

As we enter the third decade of the AIDS epidemic, it is apparent that a large number of cancers are more common in people with the human immunodeficiency virus type 1 (HIV). Non-Hodgkin’s lymphoma (NHL) remains the second most common tumour in such patients. At the onset of the epidemic, dose-inten...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2004-05, Vol.30 (3), p.249-253
Main Authors: Stebbing, Justin, Marvin, Vanessa, Bower, Mark
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
AIDS
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antiretroviral Therapy, Highly Active - methods
Chemotherapy
Drug Therapy, Combination
Evidence-Based Medicine
Female
HIV
Human immunodeficiency virus 1
Humans
Infusions, Intravenous
Lymphoma
Lymphoma, AIDS-Related - diagnosis
Lymphoma, AIDS-Related - drug therapy
Lymphoma, AIDS-Related - epidemiology
Lymphoma, Non-Hodgkin - diagnosis
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - epidemiology
Male
Middle Aged
Non-Hogdkin’s lymphoma
Primary cerebral lymphoma
Prognosis
Randomized Controlled Trials as Topic
Recurrence
Risk Assessment
Severity of Illness Index
Survival Analysis
Treatment Outcome
United Kingdom - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As we enter the third decade of the AIDS epidemic, it is apparent that a large number of cancers are more common in people with the human immunodeficiency virus type 1 (HIV). Non-Hodgkin’s lymphoma (NHL) remains the second most common tumour in such patients. At the onset of the epidemic, dose-intense combination regimens were used but these were quickly abandoned in favour of dose-modified strategies because of difficulties in tolerating aggressive chemotherapy in the presence of underlying immunosuppression. With the improvements in supportive care including more effective anti-retroviral therapies, colony-stimulating factors and prophylaxis against opportunistic infections, we are returning to the traditional chemotherapeutic approaches similar to those utilised in the non-HIV infected individual including infusional regimens. In this review, we discuss the evidence for choosing particular therapies in patients with AIDS-related NHL.
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2003.12.004